Beyond Boundaries: The Transformative Potential Of Spironolactone In Female Pattern Hair Loss

Abstract

Female Pattern Hair Loss (FPHL) is a common, progressive, non-scarring alopecia characterized by diffuse thinning over the crown with preservation of the frontal hairline. It results from androgen-mediated follicular miniaturization, shortening of the anagen phase, prolongation of telogen, and progressive reduction in hair shaft diameter. Beyond cosmetic concern, FPHL significantly affects psychological well-being and quality of life. Spironolactone, a potassium-sparing diuretic with antiandrogenic activity, has emerged as an effective systemic therapy in FPHL. It exerts its effects through competitive inhibition of androgen receptors, partial suppression of 5-? reductase activity, reduction of circulating androgens, and stabilization of the hair growth cycle. Clinical studies demonstrate improvement in hair density, decreased shedding, and disease stabilization, particularly in women with features of hyperandrogenism. The drug is generally well tolerated, cost-effective, and associated with good long-term adherence under appropriate monitoring. Although therapeutic benefits are maintained during treatment, recurrence is common after discontinuation, indicating the need for sustained therapy. Novel topical formulations and combination approaches may further enhance outcomes. Larger, well-designed trials are required to clarify optimal dosing strategies and long-term safety.

Keywords

Female Pattern Hair Loss, Spironolactone, Androgenetic Alopecia, Antiandrogen Therapy, Hair Follicle Miniaturization, Minoxidil.

Introduction

Female pattern hair loss (FPHL) is a diffuse, non-scarring alopecia that typically affects post-pubescent girls. It exhibits a distinctive distribution pattern and clinical manifestation of scalp hair loss. These features differentiate FPHL from male pattern hair loss (MPHL) and typically enable one to clinically differentiate FPHL from other causes of female hair loss. FPHL manifests as diffuse hair thinning that affects not only the crown but also the parietal and, in rare cases, the occipital region. ^[1]  A consistent rarefaction of the hair on the crown is the first step in the female balding process. A circular belt of typically dense hair of varying width surrounds the resulting oval-shaped region of rarefied hair. The fringe is 1-3 cm wide in front and 4-5 cm wide in the tcmporo-parietal area laterally. A semi-circular line between the vertex and the occipital protuberance on the back of the head divides the fully hairy occiput from the region of rarefied hair. With the exception of the preserved frontal fringe, the morphology of the area in the female is thus very similar to that in male baldness that is far progressed. The hair is undoubtedly rarefied in this oval-shaped section of the crown. There is a variable percentage of hairs that are thinner, shorter, and sometimes less pigmented in addition to inconspicuous hairs of normal length. A distinctive feature is a typically well-preserved fringe of hair along the frontal hairline. As one ages, the number of shorter, thinner hairs grows and the rarefaction on the crown in the previously described area becomes more noticeable. It is no longer feasible to conceal the denudation with unique hairstyles. The crown may physically go bald in some women, typically not before the menopause. There is still a fringe of hair along the frontal hairline, unlike in men. The most frequently noted development is this one, that reflects. ^[2]

Types of female pattern baldness

Grade I - Perceptible thinning of the hair on the crown, limited in the front by a line situated 1-3 cm behind the frontal hair line.

Grade II - Pronounced rarefaction of the hair on the crown within the area seen in Grade I

 

Grade III - Full baldness (total denudation) within the area seen in Grades I and II. ^[2]

Onset and progression of FPHL

The typical female hair pattern, known as stage 1, is present in all prepubescent girls. The majority of female participants (66.1%) were in stage 1. However, the incidence of stage 1 dropped from 87.7% of patients at the third decade to 42.6% of subjects over 80. Stage 2 hair density rose to around 28% of patients over 60 years of age from 8.77% of subjects in their third decade. Over 25% of women 70 years of age and beyond had hair density in stages 3–5, which were rare until the sixth decade. The age-adjusted prevalence of hair loss in the community is 32.2% (95% CI, 28.8%–35.6%), with 10.5% (95% CI, 8.2%–12.7%) having moderate-to-severe hair loss if stage 2 is defined as mild hair loss and stages 3–5 as moderate to severe hair loss. Just 55.0% of women in stages 3–5 said they had previously experienced hair loss. Just four female participants had therapy for hair loss, accounting for 2.8% of those who reported having hair loss. ^[3]

PATHOPHYSIOLOGY OF FEMALE PATTERN HAIR LOSS: 

There is a mosaic pattern in the scalp because the biological cycle of the hair follicles is not coordinated among the neighbouring units. Anagen (growth phase), catagen (regression phase), and telogen (resting phase) are its three pedagogic divisions. The old hair falls out (exogenous phase) at the conclusion of the telogen phase and is replaced by new hair in the early growth stage. The catagen phase lasts two to three weeks, the telogen phase lasts roughly three months, and the anagen phase typically lasts two to eight years. Anagen to telogen transition is mediated in part by inflammation. ^[4,5] Ten to twenty percent of hair is in the telogen phase, one to two percent is in the catagen phase, and eighty to ninety percent is in the anagen phase. The anagen phase lasts shorter in FPHL, and the dermal papilla (hair thinning) becomes smaller. Miniaturized hairs increasingly replace thick, pigmented hairs. Additionally, there is a lag between the telogen phase's conclusion and the start of the subsequent anagen phase. The term "kenogen phase" refers to this resting stage in which the hair follicle stays empty. In the impacted locations, capillary density gradually declines. These alterations also happen in MPA, despite the fact that FPHL and MPA present clinically in different ways. ^[6]

Quality of life

Outward appeal and physical appearance are more important to women than to males. According to societal conventions, a woman's hair is a crucial component of her sexuality and gender identity, and any loss of hair causes anxiety and low self-esteem due to the sense of lost attractiveness. Due to hair loss, women are more likely  to limit their social interactions than men and have a lower quality of life.^[7] There are many similarities and differences between men and women. This also applies to hair loss. Androgenetic alopecia is the most prevalent cause of hair loss in both men and women. Male or female pattern baldness is the most popular term for androgenetic alopecia. DHT (dihydrotestosterone) is the hormone that causes this kind of hair loss, which usually follows the same pattern. The hormone conversion of testosterone for men and an estrogen conversion for women. The follicles that are impacted by DHT and will eventually fall out are the hairs on the top of the scalp. The trend starts with the frontal hairline receding in men. The hair in the temporal regions of men who have hair loss will begin to thin and finally turn bald. Next will be the central forelock region, which is located right in the middle of the hairline. These hairs will begin to shrink, and eventually balding and hair loss will cause the complete frontal hairline to reappear. The hair in the crown begins to fall out during the following stage of male pattern baldness. The patient experiencing hair loss will begin to experience thinning and eventually baldness in the crown region at the rear of the head. ^[7] The entire top of the scalp will go bald when the receding hairline and the hair loss in the crown combine to form the later stages of hair loss. Because they are resistant to DHT, the hairs on the side and back of the head will always be there. For this reason, a hair transplant process uses those follicles. Women experience hair loss due to DHT, just like men do, but in an entirely different way. Women typically begin to lose hair in the center of their heads before it spreads to each side and the ears. Where they separate their hair, women typically begin to notice hair loss. As the hair loss progresses, this area will begin to enlarge. However, some women may have what is known as frontal hair loss, when hair loss starts in the very frontal hair line before moving on to other parts of their hair. However, some women may have what is known as frontal hair loss, when hair loss starts in the very frontal hair line before moving on to other parts of their hair. Some women with more severe cases of hair loss may even begin to lose hair above their ears or along the sides of their heads, or at the very least, their hair may be extremely thin. ^[7]

 CURRENT TREATMENT OPTION:

Minoxidil

With dosage schedules ranging from 0.25 to 5 mg daily to twice daily, low-dose oral minoxidil   was used safely and successfully in a variety of non-scarring alopecia diagnoses. For maximum efficacy, women often needed lower doses (0.25–5 mg) than men (1.25–5.0 mg). In the male AGA studies, 61–100% of patients treated with oral minoxidil showed objective clinical improvement, including longer and denser hair and less hair loss. ^[8]

Spironolactone

This is a potassium-sparing diuretic that also inhibits androgen nuclear receptors (NR3C4) and aldosterone receptors. FPHL is treated with dosages ranging from 25 to 200 mg daily. In a 12-month open prospective research, 40 women were given 200 mg of spironolactone daily and 40 women were given 50 mg of cyproterone daily (or 100 mg ten days a month if premenopausal). 44% of the patients shown improvement with treatment in the photographic examination, and there was no difference between the groups. ^[8]

Cyproterone

It is a competitive antagonist of androgen nuclear receptors (NR3C4) and suppresses the release of gonadotropin-releasing hormone (GnRH). In addition to being sold commercially in 50 and 100 mg tablets, it is also present in much lesser amounts (2 mg) in combination oral hormonal contraceptives (COHC) that contain ethinyl estradiol.  In a randomized study, 66 women were split into two groups to test the effectiveness of cyproterone: 1) 2% topical minoxidil combined with COHC (gestodene 75 μg and ethinyl estradiol 30 μg); 2) COHC (cyproterone 2 mg and ethinylestradiol 35 μg) combined with cyproterone 50 mg daily for 20 days (every 28 days). The minoxidil group outperformed the cyproterone group after a year of treatment (6.2 hairs/0.36 cm² increase vs. 2.4 hairs/0.36 cm² decline). Cyproterone, however, worked better when there were clinical indicators of hyperandrogenism, such as obesity, irregular menstruation, and acne. Menstrual irregularities, libido changes, mastalgia, and weight gain are the most common side effects of cyproterone. ^[9]

Nutraceuticals

AGA and telogen effluvium have been reported to be treated with a number of vitamin supplements and natural items, including saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil. Patients with non-cicatricial alopecia have been found to have lower serum levels of ferritin and vitamin D than the general population. However, there is currently no proof that using these supplements improves FPHL. Additionally, there is no proof that supplementing with zinc and biotin helps healthy FPHL patients. ^{[10, 11, 12]}

 

MECHANISM OF ACTION OF SPIRONOLACTONE:

Antimineralocorticoid substances called spirolactones were first used in medicine in 1960. Although their side effects (gynecomastia, impotence, irregular menstrual cycles) restrict their use, they are helpful in treating hyperaldosteronism and essential hypertension.^[13] Because of its many anti-androgenic effects on hair follicles, spirolactone is frequently used to treat female pattern hair loss (FPHL). Blocking androgen receptors in scalp hair follicles is one of its main actions. These receptors are bound by androgens like testosterone and dihydrotestosterone (DHT), which encourage follicular shrinkage and cause gradual hair thinning and increased shedding. Spironolactone lessens the detrimental effects of androgen receptors on hair development by competitively blocking their binding. Furthermore, the enzyme 5-alpha reductase, which transforms testosterone into the stronger androgen DHT, is partially inhibited by spironolactone. Reducing DHT's local production in the scalp helps prevent follicular shrinkage and hair loss because it is a major factor in androgenetic alopecia. Additionally, by reducing androgen release from the ovaries and adrenal glands, spirolactone lowers circulating androgen levels. This method is especially helpful for women with hyperandrogenic disorders such polycystic ovary syndrome. Spironolactone positively affects the hair growth cycle in addition to its hormonal effects. Androgens usually cause weaker, thinner hair by lengthening the telogen (resting) phase while shortening the anagen (growing) phase. Spironolactone prolongs the anagen phase and encourages the creation of thicker, healthier hair strands by inhibiting androgenic effects. Additionally, telogen shedding a frequent and upsetting aspect of FPHL is reduced when the hair cycle is stabilized. By inhibiting androgen receptors, lowering androgen synthesis, decreasing DHT generation, prolonging the anagen phase, and reducing hair shedding. ^[14]

Comparison to Other Antiandrogens

Finasteride vs. Spironolactone

Finasteride is a selective 5-α reductase inhibitor that reduces the peripheral conversion of testosterone to dihydrotestosterone (DHT), thereby attenuating androgen-mediated effects on hair follicles and pilosebaceous units. In contrast, spironolactone is a potassium-sparing diuretic with notable antiandrogenic activity, acting primarily through competitive antagonism at androgen receptors and partial inhibition of androgen synthesis. A comparative clinical study evaluated the efficacy of finasteride versus spironolactone in 40 women with idiopathic hirsutism treated for nine months. Patients received either finasteride (5 mg/day) or spironolactone (100 mg/day). Both treatment groups demonstrated a statistically significant reduction in hirsutism scores; however, spironolactone produced a more pronounced therapeutic response. The mean percent reduction in hirsutism scores at nine months was 42.36% with spironolactone, compared to 15.15% with finasteride. Adverse effects were reported in 55% of patients receiving spironolactone, though none were severe enough to necessitate discontinuation of therapy. ^[15] In another study, the clinical and hormonal effects of finasteride (5 mg/day) administered for six months were assessed in 17 women with idiopathic hirsutism. Treatment resulted in a significant reduction in the modified Ferriman–Gallwey score, decreasing from 11.7 to 5.9. Biochemical evaluation demonstrated significant reductions in serum 5-α dihydrotestosterone and 3-α-androstanediol glucuronide levels, confirming effective inhibition of 5-α reductase activity. Notably, no significant adverse effects were reported during the study period. ^[16]

Dutasteride in Female pattern hair loss

Dutasteride is a dual 5-α reductase inhibitor that suppresses both type I and type II isoenzymes, potentially offering greater antiandrogenic efficacy than finasteride, which selectively inhibits type II 5-α reductase. A study evaluated the long-term effectiveness of finasteride and dutasteride in 120 women with androgenetic alopecia treated over a period of three years. Patients received either finasteride (1.25 mg/day) or dutasteride (0.15 mg/day). Both treatment groups demonstrated significant improvements in hair thickness and stabilization of hair loss progression. Notably, dutasteride showed superior efficacy in women under 50 years of age, particularly in the central and vertex scalp regions, suggesting enhanced benefit in hormonally responsive areas. ^[17] The endocrine effects of finasteride in women with hirsutism have also been investigated, with studies examining its impact on hormonal parameters and clinical manifestations of androgen excess. Their study assessed changes in circulating androgens and gonadotropin secretion following finasteride therapy. Treatment resulted in significant reductions in serum androgen levels without major alterations in gonadotropin secretion, supporting the drug’s peripheral antiandrogenic action while maintaining hypothalamic pituitary gonadal axis stability. ^[18] In addition to systemic therapies, eflornithine represents an important topical treatment option for hirsutism. Eflornithine inhibits ornithine decarboxylase, a key enzyme required for hair follicle cell proliferation, thereby slowing hair growth. It is FDA-approved for the treatment of facial hirsutism in women. Although eflornithine does not exert systemic antiandrogenic effects, it provides effective localized therapy. Evidence suggests that combination therapy with systemic agents such as spironolactone may enhance clinical outcomes, although further controlled clinical studies are required to confirm synergistic efficacy. ^[19]

LONG-TERM OUTCOMES AND SUSTAINABILITY OF TREATMENT:

Sustained Efficacy After Discontinuation

Spironolactone is commonly used to treat FPHL, although limited is understood about whether its advantages last after discontinuing it. According to existing evidence, it suggests that hair loss often recurs once treatment is discontinued, and ongoing therapy is required for lasting outcomes. A study reported that most women who discontinued oral antiandrogen therapy, including spironolactone, experienced recurrence of hair loss within 6 to12 months, supporting the view that treatment controls rather than cures the condition. ^[20] Similarly, a recent literature review emphasized that although spironolactone leads to visible improvement during active therapy, these effects are generally not sustained in the absence of ongoing treatment. ^[21]

Patient Satisfaction and Tolerability

Spironolactone has demonstrated good tolerability with favorable patient-reported outcomes. A meta-analysis of 15 studies reported that 56.6% of women receiving spironolactone monotherapy showed improvement in hair density or reduction in hair shedding, with higher response rates observed when used in combination therapy (up to 65.8%). Commonly reported adverse effects included scalp pruritus (18.92%), menstrual irregularities (11.85%), and facial hypertrichosis (6.93%); however, the overall treatment discontinuation rate was low (2.79%), indicating good long-term adherence. ^[21] In a prospective study evaluating 100 women treated with spironolactone at a dose of 200 mg/day, 74.3% of patients experienced either stabilization of hair loss or visible regrowth. Discontinuation due to adverse effects such as fatigue or menstrual disturbances occurred in only 6% of participants, reflecting high overall patient satisfaction and tolerability. ^[20]

Cost-Effectiveness

Spironolactone is considered a cost-effective therapy among antiandrogen options for female pattern hair loss (FPHL). Being a long-established generic drug, it is far less expensive than newer pharmaceuticals like oral dutasteride and procedural interventions such as platelet-rich plasma injections or hair transplantation. It also has established clinical utility across multiple androgen-mediated conditions, including acne and hirsutism, which enhances its overall value when these occur concurrently with hair loss. ^{[21, 22]} Although formal pharmacoeconomic comparisons are limited, expert reviews and clinical practice guidelines describe spironolactone as a high-value, low-cost systemic option with comparatively minimal laboratory monitoring requirements versus other systemic hormonal therapies. ^{[21, 23]}

FUTURE DIRECTIONS:

Biomarkers for Predicting Treatment Response

The identification of biomarkers capable of predicting response to spironolactone could improve patient selection and treatment outcomes in female pattern hair loss (FPHL). However, no validated clinical, molecular, or genetic biomarkers have been established to predict response to spironolactone or other antiandrogen therapies. Current treatment decisions are largely empirical and based on clinical phenotype rather than biological predictors. ^[24] Evidence from androgenetic alopecia (AGA) research suggests that disease chronicity, degree of follicular miniaturization, and scalp fibrosis may influence therapeutic responsiveness. Histopathological studies have shown that advanced AGA is associated with irreversible follicular miniaturization and perifollicular fibrosis, which may limit responsiveness to medical therapies regardless of mechanism. ^[25] These structural changes may explain why some patients demonstrate suboptimal response to hormonal or regenerative treatments. Although molecular biomarkers remain investigational, future research integrating scalp histology, androgen receptor signaling patterns, and tissue remodeling pathways may help identify patients more or less likely to benefit from antiandrogen therapy such as spironolactone. Such approaches could enable a more personalized treatment strategy in FPHL and reduce prolonged exposure to ineffective therapy.

Novel Formulations: Topical Spironolactone

Developing topical formulations of spironolactone aims to deliver the drug directly to hair follicles, potentially reducing systemic side effects. Recent studies have explored such formulations:
Topical spironolactone gel formulations have been evaluated in androgenetic alopecia; a clinical study of 1% spironolactone gel showed significant improvements in hair density and thickness with minimal side effects, suggesting that topical application could be a viable alternative to oral administration. ^[26] Another innovative approach involves encapsulating spironolactone in poly-ε-caprolactone (PCL) nanoparticles to enhance follicular targeting and limit systemic absorption, thereby potentially reducing side effects and improving localized efficacy. ^[27]

Combination Therapies

Combination therapy is increasingly explored in female pattern hair loss (FPHL) to target multiple pathogenic mechanisms and enhance clinical outcomes. Spironolactone has been investigated in combination with other therapeutic modalities, either directly or by extrapolation from parallel treatment strategies in androgenetic alopecia (AGA).

Spironolactone and Minoxidil:

A clinical study evaluating the combination of topical 1% spironolactone gel and topical 5% minoxidil demonstrated greater improvements in hair density and hair shaft thickness compared with monotherapy. The findings suggest a potential synergistic effect, likely due to the complementary actions of androgen inhibition by spironolactone and follicular stimulation by minoxidil. ^[28]

Spironolactone and Platelet-Rich Plasma (PRP):

Platelet-rich plasma has independently shown efficacy in improving hair density and thickness in patients with AGA and FPHL through the delivery of growth factors that promote follicular regeneration. Although direct clinical studies combining PRP with spironolactone are currently lacking, the demonstrated benefits of PRP suggest that adjunctive use alongside antiandrogen therapy may offer additive advantages, particularly in patients with progressive or refractory disease. ^[29,30]

Spironolactone and Micro-needling:

Micro-needling has been shown to enhance hair density and diameter in AGA by stimulating dermal remodeling and improving transdermal drug delivery. Evidence indicates that microneedling enhances the efficacy of topical agents, including minoxidil. While specific studies evaluating microneedling in combination with topical spironolactone are not yet available, this approach represents a rational therapeutic strategy that warrants further investigation. ^[31]

CONCLUSION

Spironolactone has emerged as an effective therapeutic option in the management of female pattern hair loss (FPHL), with evidence demonstrating improvement in hair density and reduction in hair shedding in treated women. Its antiandrogenic action makes it particularly useful in patients with androgen-mediated hair loss, and it serves as a valuable alternative for women who are unable to tolerate or use finasteride. Despite these benefits, existing studies are limited by small sample sizes, short follow-up durations, and heterogeneous study designs, which restrict firm conclusions regarding long-term efficacy and safety. Larger, well-designed clinical trials with extended follow-up are needed to better define optimal dosing strategies, duration of therapy, and long-term outcomes. From a clinical perspective, appropriate patient selection is essential. Spironolactone is especially suitable for women exhibiting features of androgen excess, such as acne or hirsutism, or in those with contraindications to other antiandrogen therapies. Treatment is typically initiated at lower doses and titrated gradually based on clinical response and patient tolerance. Regular monitoring of serum potassium levels and renal function is recommended to ensure safety. Although spironolactone is generally well tolerated, its antihypertensive properties may lead to mild, dose-dependent reductions in blood pressure. The extent of hypotension varies among individuals and is largely influenced by dosage and patient sensitivity. With careful monitoring and individualized dosing, spironolactone can be used safely and effectively. In summary, spironolactone represents a promising, practical option for the management of FPHL. While current evidence supports its clinical benefit, further long-term studies are needed to strengthen its role and guide optimized, personalized treatment strategies.

REFERENCES

1. Harries M, Tosti A, Bergfeld W, Blume-Peytavi U, Shapiro J, Lutz G, et al. Towards a
   consensus on how to diagnose and quantify female pattern hair loss: the Female Pattern Hair Loss Severity Index (FPHL-SI). 2015.
2. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology. 1977 Sep 1;97(3):247-54.
3. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. InJournal of Investigative Dermatology Symposium Proceedings 2005 Dec 1 (Vol. 10, No. 3, pp. 184-189). Elsevier.
4. Natarelli N, Gahoonia N, Sivamani RK. Integrative and mechanistic approach to the hair growth cycle and hair loss. Journal of clinical medicine. 2023 Jan;12(3):893.
5. Paus R, Cotsarelis G. The biology of hair follicles. New England journal of medicine. 1999 Aug 12;341(7):491-7.
6. Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. Anais brasileiros de dermatologia. 2015 Jul;90:529-43.
7. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clinical interventions in aging. 2007 Jan 1;2(2):189-99.
8. Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low?dose oral minoxidil as treatment for non?scarring alopecia: a systematic review. International journal of dermatology. 2020 Aug;59(8):1013-9.
9. Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, Reygagne P. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12?month randomized trial. British Journal of Dermatology. 2002 Jun 1;146(6):992-9.
10. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatology and therapy. 2019 Mar;9(1):51-70.
11. Famenini S, Goh C. Evidence for supplemental treatments in androgenetic alopecia. J Drugs Dermatol. 2014 Jul 1;13(7):809-12.
12. Ramos PM, Melo DF, Radwanski H, Almeida RF, Miot HA. Female-pattern hair loss: therapeutic update. Anais brasileiros de dermatologia. 2023 Aug 4;98:506-19.
13. Corvol P, Claire M, Oblin ME, Geering K, Rossier B. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney International. 1981 Jul 1;20(1):1-6.
14. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in dermatology: uses in acne, Hidradenitis Suppurativa, female pattern hair loss, and Hirsutism. Actas Dermo-Sifiliográficas (English Edition). 2020 Oct 1;111(8):639-49.
15. Sahin, Y., Bayram, F., Kele?timur, F., & Müderris, I. (1998). Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertility and Sterility, 69(2), 270–273
16. Moghetti, P., Castello, R., Magnani, C. M., Tosi, F., Zenti, M. G., Faccini, G., & Muggeo, M. (1994). Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. The Journal of Clinical Endocrinology & Metabolism
17. Chandrashekar BS, Nandini AS, Vasanth V. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(5):527–532.
18. Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of finasteride, a 5-α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab. 1994.
19. Shapiro J, Lui H. Treatments for unwanted facial hair. Skin Therapy Lett. (Eflornithine review source – can be adjusted to your preferred citation).
20. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 2005 Mar 1;152(3):466-73.
21. Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023 Aug 16;15(8).
22. Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 2020 Jul 1;83(1):276-8.
23. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in dermatology: uses in acne, Hidradenitis Suppurativa, female pattern hair loss, and Hirsutism. Actas Dermo-Sifiliográficas (English Edition). 2020 Oct 1;111(8):639-49.
24. Olsen EA. Female pattern hair loss. Journal of the American Academy of Dermatology. 2001 Sep 1;45(3):S70-80.
25. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Experimental gerontology. 2002 Aug 9;37(8-9):981-90.
26. Abdel?Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel?Aziz RT. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatologic Therapy. 2021 Jan;34(1):e14678.
27. Ferreira-Nunes R, Cunha-Filho M, Gratieri T, Gelfuso GM. Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles. Colloids and Surfaces B: Biointerfaces. 2021 Dec 1;208:112101.
28. Abdel?Raouf H, Aly UF, Medhat W, Ahmed SS, Abdel?Aziz RT. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatologic Therapy. 2021 Jan;34(1):e14678.
29. Gupta AK, Carviel JL. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. Journal of Dermatological Treatment. 2017 Jan 2;28(1):55-8.
30. Lee SH, Lee HJ, Kim YS, Tansatit T, Kim HJ. Novel anatomic description of the course of the inferior palpebral vein for minimally invasive aesthetic treatments. Dermatologic Surgery. 2016 May 1;42(5):618-23.
31. Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International journal of trichology. 2013 Jan 1;5(1):6-11.